Full Text
Additional Clinical Benefit for Patient Relevant Endpoints- Investment Disincentives by AMNOG in the Example of Parkinson’s Disease

Abstract

Authors

S. Walzer B. Holbein

Back to Volume 16, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×